HARRISON F. FLIPPIN, M.D., F.A.C.P.; LEON SCHWARTZ, M.D.; JEFFERSON H. CLARK, M.D., F.A.C.P.
The introduction of sulfapyridine and sulfathiazole in the treatment of pneumococcic pneumonia constitutes the greatest advance in the control of this disease. Within the past three years numerous clinical reports have unquestionably established their therapeutic effectiveness, and the fatality rate of pneumococcic pneumonia has been markedly reduced with their use. Despite the proved value of this form of therapy, a certain percentage of pneumonia patients in whom these drugs are employed fail to recover. The purpose of this paper is to discuss the influence of several factors on the prognosis of this disease. This report is based on our experience
FLIPPIN HF, SCHWARTZ L, CLARK JH. FACTORS INFLUENCING THE FATALITY RATE OF PNEUMOCOCCIC PNEUMONIA TREATED WITH SULFONAMIDE COMPOUNDS(FACTORS INFLUENCING THE FATALITY RATE OF PNEUMOCOCCIC PNEUMONIA TREATED WITH SULFONAMIDE COMPOUNDS*). Ann Intern Med. 1941;14:1969–1974. doi: 10.7326/0003-4819-14-11-1969
Download citation file:
Published: Ann Intern Med. 1941;14(11):1969-1974.
Infectious Disease, Pneumonia, Pulmonary/Critical Care.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use